Evidence map›Paper›PMID 37141492›Full record

ArticleJournal of chemical information and modeling2023

Screening and Biological Evaluation of Soluble Epoxide Hydrolase Inhibitors: Assessing the Role of Hydrophobicity in the Pharmacophore-Guided Search of Novel Hits.

Javier Vázquez, Tiziana Ginex, Albert Herrero, Christophe Morisseau, Bruce D Hammock, F Javier Luque

Open access · hybridAbstract read
In one paragraph

Article in Journal of chemical information and modeling, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.0field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Javier VázquezDepartament de Nutrició, Ciències de l'Alimentació i Gastronomia, Facultat de Farmàcia i Ciències de l'Alimentació, Institut de Biomedicina (IBUB), Prat de la Riba 171, 08921 Santa Coloma de Gramenet, Spain.ORCID 0000-0003-4400-6378
Tiziana GinexDepartament de Nutrició, Ciències de l'Alimentació i Gastronomia, Facultat de Farmàcia i Ciències de l'Alimentació, Institut de Biomedicina (IBUB), Prat de la Riba 171, 08921 Santa Coloma de Gramenet, Spain.
Albert HerreroPharmacelera, Parc Científic de Barcelona (PCB), Baldiri Reixac 4-8, 08028 Barcelona, Spain.
Christophe MorisseauDepartment of Entomology and Nematology, and Comprehensive Cancer Center, University of California, Davis, One Shields Avenue, Davis, California 95616, United States.
Bruce D HammockDepartment of Entomology and Nematology, and Comprehensive Cancer Center, University of California, Davis, One Shields Avenue, Davis, California 95616, United States.ORCID 0000-0003-1408-8317
F Javier LuqueDepartament de Nutrició, Ciències de l'Alimentació i Gastronomia, Facultat de Farmàcia i Ciències de l'Alimentació, Institut de Biomecidina (IBUB) and Institut de Química Teòrica i Computacional (IQTCUB), Prat de la Riba 171, 08921 Santa Coloma de Gramenet, Spain.ORCID 0000-0002-8049-3567
University of California, Davis · US

Funding

Workshop on Environmental Technology Transfer and EntrepreneurshipP42ES004699 · NIEHS · UNIVERSITY OF CALIFORNIA DAVIS · PI HAMMOCK, BRUCE D · 1987 to 2021
$50.1M
UC Davis CounterACT Center of Excellence: Developing Therapeutic Strategies for Mitigating the Chronic Neurological Consequences of Acute Organophosphate IntoxicationU54NS127758 · NINDS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Amy R. Brooks-Kayal, Pamela J Lein · 2022 to 2026
$17.2M
Supplement for bioactive lipids as effectors and indicators of the deleterious effects of human healthR35ES030443 · NIEHS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI MORISSEAU, CHRISTOPHE HP · 2019 to 2025
$5.8M
NIEHS NIH HHS P42 ES004699NIEHS NIH HHS R35 ES030443NINDS NIH HHS U54 NS127758
6 · The paper itself

Abstract

The human soluble epoxide hydrolase (sEH) is a bifunctional enzyme that modulates the levels of regulatory epoxy lipids. The hydrolase activity is carried out by a catalytic triad located at the center of a wide L-shaped binding site, which contains two hydrophobic subpockets at both sides. On the basis of these structural features, it can be assumed that desolvation is a major factor in determining the maximal achievable affinity that can be attained for this pocket. Accordingly, hydrophobic descriptors may be better suited to the search of novel hits targeting this enzyme. This study examines the suitability of quantum mechanically derived hydrophobic descriptors in the discovery of novel sEH inhibitors. To this end, three-dimensional quantitative structure-activity relationship (3D-QSAR) pharmacophores were generated by combining electrostatic and steric or alternatively hydrophobic and hydrogen-bond parameters in conjunction with a tailored list of 76 known sEH inhibitors. The pharmacophore models were then validated by using two external sets chosen (i) to rank the potency of four distinct series of compounds and (ii) to discriminate actives from decoys, using in both cases datasets taken from the literature. Finally, a prospective study was performed including a virtual screening of two chemical libraries to identify new potential hits, which were subsequently experimentally tested for their inhibitory activity on human, rat, and mouse sEH. The use of hydrophobic-based descriptors led to the identification of six compounds as inhibitors of the human enzyme with IC

Indexed as

Epoxide HydrolasesPharmacophoreAnimalsEnzyme InhibitorsHumansHydrophobic and Hydrophilic InteractionsMiceProspective StudiesQuantitative Structure-Activity RelationshipRatsEnzyme InhibitorsEpoxide Hydrolases

Identifiers

PMID37141492
PMCPMC10207366
OpenAlexW4368617590

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.